ストックスクリーナーアプリを入手
14.43
1.57%
-0.23
アフターアワーズ：
14.66
0.23
+1.59%
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
Acadia Pharmaceuticals (ACAD) Sees Price Target Cut by UBS | ACA - GuruFocus
UBS Adjusts ACADIA Pharmaceuticals Price Target to $22 From $25, Maintains Buy Rating - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025 - BioSpace
Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Acadia Pharmaceuticals (ACAD) Price Target Lowered by BofA Before Q1 Earnings | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals price target lowered to $18 from $19 at BofA - MSN
BofA Adjusts Price Target on ACADIA Pharmaceuticals to $18 From $19, Keeps Neutral Rating - marketscreener.com
Schizophrenia Market to Reach New Heights in Growth by 2034, - openPR.com
Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? - Yahoo Finance
Lobbying Update: $20,000 of ACADIA PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Li - GuruFocus
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar? - Yahoo Finance
Acadia Pharmaceuticals principal accounting officer sells $15,234 in stock By Investing.com - Investing.com South Africa
Acadia Pharmaceuticals principal accounting officer sells $15,234 in stock - Investing.com Australia
Acadia Pharmaceuticals CFO sells $40,132 in stock By Investing.com - Investing.com India
Acadia Pharmaceuticals CFO sells $40,132 in stock - Investing.com
ACADIA Pharmaceuticals Executives Sell Shares to Cover Taxes - TradingView
Is Weakness In ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - simplywall.st
RBC Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire
ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - Fierce Pharma
Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - Marketscreener.com
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - Yahoo Finance
Acadia Pharmaceuticals principal accounting officer sells $18k in stock By Investing.com - Investing.com Canada
Acadia Pharmaceuticals CFO sells $54,065 in stock By Investing.com - Investing.com Canada
Acadia Pharmaceuticals CFO sells $54,065 in stock - Investing.com India
Acadia Pharmaceuticals principal accounting officer sells $18k in stock - Investing.com
Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Psychosis in Parkinson's and Alzheimer's Disease Market: - openPR
Parkinson's Disease Psychosis Treatment Market Size in 7MM - openPR
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis - Business Wire
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome - Business Wire
Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now? - Insider Monkey
ACADIA Pharmaceuticals Earns RS Rating Upgrade - Investor's Business Daily
Former San Diego Pharma VP pleads guilty to securities fraud for insider trading - MSN
Ryan Reynolds Announces More to Parkinson’s® Campaign - Business Wire
Acadia Pharmaceuticals issues new employee stock awards By Investing.com - Investing.com Australia
Acadia Pharmaceuticals issues new employee stock awards - Investing.com India
0.78%
2.03%
大文字化:
|
ボリューム (24 時間):